High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis : A Network Meta-Analysis
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Migraine is a highly prevalent neurologic disorder with prevalence rates ranging from 9% to 18% worldwide. Current pharmacologic prophylactic strategies for migraine have limited efficacy and acceptability, with relatively low response rates of 40% to 50% and limited safety profiles. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are considered promising therapeutic agents for migraine prophylaxis. The aim of this network meta-analysis (NMA) was to compare the efficacy and acceptability of various dosages of EPA/DHA and other current Food and Drug Administration-approved or guideline-recommended prophylactic pharmacologic interventions for migraine. Randomized controlled trials (RCTs) were eligible for inclusion if they enrolled participants with a diagnosis of either episodic or chronic migraine. All NMA procedures were conducted under the frequentist model. The primary outcomes assessed were 1) changes in migraine frequency and 2) acceptability (i.e., dropout for any reason). Secondary outcomes included response rates, changes in migraine severity, changes in the frequency of using rescue medications, and frequency of any adverse events. Forty RCTs were included (N = 6616; mean age = 35.0 y; 78.9% women). Our analysis showed that supplementation with high dosage EPA/DHA yields the highest decrease in migraine frequency [standardized mean difference (SMD): -1.36; 95% confidence interval (CI): -2.32, -0.39 compared with placebo] and the largest decrease in migraine severity (SMD: -2.23; 95% CI: -3.17, -1.30 compared with placebo) in all studied interventions. Furthermore, supplementation with high dosage EPA/DHA showed the most favorable acceptability rates (odds ratio: 1.00; 95% CI: 0.06, 17.41 compared with placebo) of all examined prophylactic treatments. This study provides compelling evidence that high dosage EPA/DHA supplementation can be considered a first-choice treatment of migraine prophylaxis because this treatment displayed the highest efficacy and highest acceptability of all studied treatments. This study was registered in PROSPERO as CRD42022319577.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Advances in nutrition (Bethesda, Md.) - 15(2024), 2 vom: 01. Feb., Seite 100163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tseng, Ping-Tao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
25167-62-8 |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.advnut.2023.100163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366006967 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366006967 | ||
| 003 | DE-627 | ||
| 005 | 20240219231936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.advnut.2023.100163 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM366006967 | ||
| 035 | |a (NLM)38110000 | ||
| 035 | |a (PII)S2161-8313(23)01450-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tseng, Ping-Tao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis |b A Network Meta-Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Migraine is a highly prevalent neurologic disorder with prevalence rates ranging from 9% to 18% worldwide. Current pharmacologic prophylactic strategies for migraine have limited efficacy and acceptability, with relatively low response rates of 40% to 50% and limited safety profiles. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are considered promising therapeutic agents for migraine prophylaxis. The aim of this network meta-analysis (NMA) was to compare the efficacy and acceptability of various dosages of EPA/DHA and other current Food and Drug Administration-approved or guideline-recommended prophylactic pharmacologic interventions for migraine. Randomized controlled trials (RCTs) were eligible for inclusion if they enrolled participants with a diagnosis of either episodic or chronic migraine. All NMA procedures were conducted under the frequentist model. The primary outcomes assessed were 1) changes in migraine frequency and 2) acceptability (i.e., dropout for any reason). Secondary outcomes included response rates, changes in migraine severity, changes in the frequency of using rescue medications, and frequency of any adverse events. Forty RCTs were included (N = 6616; mean age = 35.0 y; 78.9% women). Our analysis showed that supplementation with high dosage EPA/DHA yields the highest decrease in migraine frequency [standardized mean difference (SMD): -1.36; 95% confidence interval (CI): -2.32, -0.39 compared with placebo] and the largest decrease in migraine severity (SMD: -2.23; 95% CI: -3.17, -1.30 compared with placebo) in all studied interventions. Furthermore, supplementation with high dosage EPA/DHA showed the most favorable acceptability rates (odds ratio: 1.00; 95% CI: 0.06, 17.41 compared with placebo) of all examined prophylactic treatments. This study provides compelling evidence that high dosage EPA/DHA supplementation can be considered a first-choice treatment of migraine prophylaxis because this treatment displayed the highest efficacy and highest acceptability of all studied treatments. This study was registered in PROSPERO as CRD42022319577 | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a DHA | |
| 650 | 4 | |a EPA | |
| 650 | 4 | |a migraine | |
| 650 | 4 | |a network meta-analysis | |
| 650 | 4 | |a polyunsaturated fatty acid | |
| 650 | 4 | |a prevention | |
| 650 | 7 | |a Fatty Acids, Omega-3 |2 NLM | |
| 650 | 7 | |a Docosahexaenoic Acids |2 NLM | |
| 650 | 7 | |a 25167-62-8 |2 NLM | |
| 650 | 7 | |a Eicosapentaenoic Acid |2 NLM | |
| 650 | 7 | |a AAN7QOV9EA |2 NLM | |
| 700 | 1 | |a Zeng, Bing-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiann-Jy |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Chun-Hsien |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Bing-Syuan |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Yu-Shian |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Cheuk-Kwan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Yu-Kang |e verfasserin |4 aut | |
| 700 | 1 | |a Stubbs, Brendon |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Andre F |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Chih-Sung |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tien-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Chih-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Suen, Mein-Woei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chun-Pai |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Shih-Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yen-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Shiue, Yow-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chao-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Kuan-Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Pao-Yen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in nutrition (Bethesda, Md.) |d 2012 |g 15(2024), 2 vom: 01. Feb., Seite 100163 |w (DE-627)NLM217136133 |x 2156-5376 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:100163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.advnut.2023.100163 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 2 |b 01 |c 02 |h 100163 | ||